
Tempus
Tempus is an American biotechnology company that provides data and AI services for the healthcare industry. The company collects genomic data from patients, organizes it, and provides insights with the help of machine learning. It has 3.5+ million patient records in its oncology dataset. Tempus' products and services are used in oncology, neurology, life sciences and infectious disease research to provide patients with personalized, targeted therapies.
Tempus offers services both directly to patients and through physicians. The company is headquartered in Chicago, Illinois.
NewsHeat chart
- Week
- Month
- Year
- Media news
- Corp news
The data in the chart above is based on data derived from our proprietary XP calculation model and may be changed, adjusted and updated without prior notice
Company Valuation
- Valuation
- Share Price
- Cumulative Funding
The data in the tables and charts is based on data from public sources and although we make every effort to compile the data, it may not coincide with the actual data of the issuer.
*** - To view the data, please log into your account or create a new one.
News related to Tempus177

Tempus Now an In-Network Provider for Blue Cross Blue Shield Illinois, Blue Shield California, and Avalon Healthcare Solutions - Tempus
Tempus, a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that the company has signed agreements for in-network provider status with Blue Cross Blue Shield (BCBS) of Illinois, Blue Shield of Ca...


Tempus Announces Four Abstracts Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium - Tempus
Tempus, a leader in artificial intelligence and precision medicine, today announced four abstracts were accepted for presentation at the 2024 San Antonio Breast Cancer Symposium, which convenes from December 10-13, in San Antonio, Texas. “Presenting our l...


Tempus to Participate in the Piper Sandler 36th Annual Healthcare Conference - Tempus
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, held in New York, New York...


Tempus Molecular Profiling Integration Now Available Through Flatiron’s OncoEMR® - Tempus
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the collaboration with Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of...


Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care - Tempus
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, “Actionable structural variant detection via RNA-NGS and DNA-NGS in patients with adva...


Investors8







